Abstract

Nin one binding (NOB1) protein has been identified as an oncogene in various human cancers, including prostate cancer. MicroRNAs (miRs) have also been recognized as novel regulatory molecules of gene expression. The present study aimed to discover potential miRs that target NOB1 and regulate NOB1 expression in prostate cancer. miR-192, which is an important regulator of numerous cancers, was found to be significantly downregulated in prostate cancer cells. Moreover, we noted that miR-192 overexpression markedly inhibited the proliferation, colony‑forming ability, and migratory capacity of the prostate cancer cells. miR-192 overexpression also induced cell cycle arrest in the G1 phase, as shown by flow cytometry. Bioinformatics analysis results revealed that NOB1 was a possible candidate target gene of miR-192. This discovery was further verified through dual‑luciferase reporter assay, RT-qPCR, and western blot analysis. We suggest that miR-192 directly regulates the mRNA and protein expression of NOB1. Furthermore, miR-192 inhibited the expression of p38 mitogen-activated protein kinase. The results of our study indicated that miR-192 negatively regulated NOB1 expression and impaired the tumorigenicity of prostate cancer cells. Therefore, we suggest that targeting miR-192 and NOB1 is a novel strategy which will assist in the development of new therapeutics that will be used in the future to prevent and treat prostate cancer.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.